Perioperative Perfusion of Allografts with Anti-Human T-lymphocyte Globulin Does Not Improve Outcome Post Liver Transplantation—A Randomized Placebo-Controlled Trial

• Published in: Journal of clinical medicine Vol. 10; no. 13; p. 2816
• Main Authors: Ritschl, Paul Viktor, Günther, Julia, Hofhansel, Lena, Ernst, Stefanie, Ebner, Susanne, Sattler, Arne, Weiß, Sascha, Weissenbacher, Annemarie, Oberhuber, Rupert, Cardini, Benno, Öllinger, Robert, Biebl, Matthias, Denecke, Christian, Margreiter, Christian, Resch, Thomas, Schneeberger, Stefan, Maglione, Manuel, Kotsch, Katja, Pratschke, Johann
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 25.06.2021; MDPI
• Subjects: Biopsy; Clinical medicine; Gene expression; Ischemia; Kidneys; Liver transplants; Patients; Thoracic surgery; Values; Germany
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10132816

Due to the lack of suitable organs transplant surgeons have to accept unfavorable extended criteria donor (ECD) organs. Recently, we demonstrated that the perfusion of kidney organs with anti-human T-lymphocyte globulin (ATLG) prior to transplantation ameliorates ischemia-reperfusion injury (IRI). Here, we report on the results of perioperative ATLG perfusion in a randomized, single-blinded, placebo-controlled, feasibility trial (RCT) involving 30 liver recipients (LTx). Organs were randomly assigned for perfusion with ATLG/Grafalon® (AP) (n = 16) or saline only (control perfusion = CP) (n = 14) prior to implantation. The primary endpoint was defined as graft function reflected by aspartate transaminase (AST) values at day 7 post-transplantation (post-tx). With respect to the primary endpoint, no significant differences in AST levels were shown in the intervention group at day 7 (AP: 53.0 ± 21.3 mg/dL, CP: 59.7 ± 59.2 mg/dL, p = 0.686). Similarly, exploratory analysis of secondary clinical outcomes (e.g., patient survival) and treatment-specific adverse events revealed no differences between the study groups. Among liver transplant recipients, pre-operative organ perfusion with ATLG did not improve short-term outcomes, compared to those who received placebo perfusion. However, ATLG perfusion of liver grafts was proven to be a safe procedure without the occurrence of relevant adverse events.